Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia

Pediatr Infect Dis J. 2015 Nov;34(11):1264-7. doi: 10.1097/INF.0000000000000859.

Abstract

Three multicenter, randomized, controlled studies evaluated doripenem in children 3 months to <18 years of age, with complicated intra-abdominal or urinary tract infections and bacterial pneumonia.In the 66 patients treated with doripenem before early termination of the studies for nonsafety reasons, doripenem was safe and generally well tolerated. Low enrollment limited ability to assess benefits and risks of doripenem in children.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems / adverse effects*
  • Carbapenems / therapeutic use
  • Child
  • Child, Preschool
  • Doripenem
  • Hospitalization
  • Humans
  • Infant
  • Intraabdominal Infections / drug therapy*
  • Pneumonia, Bacterial / drug therapy*
  • Treatment Outcome
  • Urinary Tract Infections / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Doripenem